Without the APOE ε4 or ε2 dosage weights, we observed similar results for the AD PHS, which was associated with increased relative risk ratios for the AD (1.86 95% CI [1.47–2.37]), AD + DLB (1.83 [1.39–2.40]), AD + MTLS (1.91 [1.37–2.65]), DLB (2.03 [1.26–3.26]), and FTD (1.78 [1.14–2.78]) groups compared to the control group. This evidence concerns the gene APOE and Alzheimer disease.